Global Perspectives on Leukemia in 2021 and Beyond

Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia

September 8 and 13, 2021

Faculty Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

FACULTY MEMBERS

Charles Mullighan, MD, FRACP, MBBS
St. Jude Children’s Research Hospital, Memphis, TN, USA

Naval Daver, MD, FRACP, MBBS
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Jorge Cortes, MD
Georgia Cancer Center, Augusta, GA, USA

Rami Komrokji, MD
H. Lee Moffit Cancer Center, Tampa, FL

Jae Park, MD
Memorial Sloan Kettering Cancer Center, New York, , USA

Eunice Wang, MD
Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

Daniel DeAngelo, MD, PhD
Dana-Farber Cancer Institute, Boston, MA, USA

Guillermo Garcia-Manero, MD
The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Jerry Radich, MD
Fred Hutchinson Cancer Research Center, Seattle, WA, USA

Neil Shah, MD, PhD
University of California, San Francisco, CA, USA

Agenda

Export meeting topics

View Agenda

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • CML: First-Line Treatment  
  • CML: Treatment of Resistant/Refractory Patients and New Targets
  • ALL: Genetic Subsets  
  • ALL: Role of Monoclonal and Bispecific Antibodies  
  • ALL: Role of CAR T Cells 
  • MDS: Low-Risk Disease 
  • MDS: High-Risk Disease 
  • AML: Newly Diagnosed Patients (including FLT3 and IDH1/2 mutated disease) 
  • AML: Relapse/Refractory Patients (including FLT3 and IDH1/2 mutated disease) 

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.